Fig. 3From: Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trialsComparison of DFS between adjuvant EGFR-TKIs versus adjuvant chemotherapy/placebo in resected NSCLC patients. A DFS for the intent-to-treat patients with regardless of the EGFR mutations status. B DFS for patients harboring EGFR mutationsBack to article page